Skip to content

Pelvic floor biofeedback training combined with vibration training for improving clinical outcomes in patients with stress urinary incontinence

Pelvic floor biofeedback training combined with vibration training for improving clinical outcomes in patients with stress urinary incontinence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125909
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress urinary incontinence

Interventions

Treatment group:The treatment group received biofeedback combined with whole-body vibration training using the Yufeng Medical Y-V3 device. Surface electromyography (sEMG) testing was performed every t
Control group:The control group received conventional biofeedback therapy using the Vishee SA9800 device. Surface electromyography (sEMG) testing was performed every three sessions to analyze changes

Sponsors

Wenzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the requirements for stress urinary incontinence as specified in the "Peking University Expert Consensus on the Diagnosis and Treatment of Female Stress Urinary Incontinence"; aged 20–60 years; normal cognitive function; able to clearly articulate symptoms; and capable of cooperating with training and follow-up visits. 2. Disease duration >=3 months; frequency of urine leakage >=2 times per week; and positive pad test result. 3. No history of invasive interventions such as pelvic floor muscle surgery or radiofrequency therapy; and no use of medications affecting bladder function within the past month. 4. Voluntary participation in this study and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Concurrent urge urinary incontinence, mixed urinary incontinence (predominantly with urge symptoms), or other types of urinary incontinence; 2. Presence of urological diseases such as bladder stones, bladder cancer, or urinary tract infection; 3. During pregnancy, lactation, or postmenopausal hormone therapy; 4. Loss to follow-up, refusal to continue participating in the study, or interruption of treatment due to personal reasons during the follow-up period; 5. Patients with severe conditions are excluded from the study.

Design outcomes

Primary

MeasureTime frame
Clinical treatment efficacy;Pelvic floor muscle strength;Surface electromyography (EMG) assessment of pelvic floor using Glazer scale;1-hour pad test;Surface electromyography (EMG) values of pelvic floor;Pelvic floor electromyography data;Pelvic floor muscle strength test results;

Countries

China

Contacts

Public ContactWang Xiaoqian

Wenzhou People's Hospital

wxq_0507@hotmail.com+86 151 6875 7582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026